Navigation Links
iBio Announces At-the-Market Equity Offering
Date:2/1/2013

NEWARK, Del., Feb. 1, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) entered into an "At-the-Market" (ATM) equity offering sales agreement with the Donjon Group, a division of Further Lane Securities, L.P. on January 31, 2013, under which iBio may, from time to time, offer and sell shares of its common stock having an aggregate offering price of up to $10 million through Donjon. iBio expects to use any proceeds from this offering for the continued development of applications of its proprietary technology, business development and for other general corporate purposes.

(Logo:  http://photos.prnewswire.com/prnh/20120419/NY91086LOGO )

Under the ATM equity offering sales agreement, sales of common stock, if any, through Donjon, will be made by means of ordinary brokers' transactions, or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices, at negotiated prices or, with iBio's prior approval, in privately negotiated transactions.

The common stock will be offered under the company's existing effective shelf registration statement (including a prospectus) filed with the Securities and Exchange Commission. A prospectus supplement related to the offering has been filed with the Securities and Exchange Commission. Any offer, solicitation or sale will be made only by means of the prospectus supplement and the accompanying prospectus. Current and potential investors should read the prospectus in the registration statement, and the prospectus supplement relating to the ATM equity offering and other documents the company has filed with the SEC for more complete information about iBio and the ATM equity offering program.

A copy of the prospectus supplement and accompanying prospectus relating to these securities may be obtained by contacting the Donjon Group c/o Further Lane Securities, L.P., 555 Madison Avenue, 25th Floor, New York, NY 10022, or by calling (646) 652-5862.

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor may there be any sale of iBio's common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any state or jurisdiction.

About iBio, Inc.

iBio develops and offers product applications of its iBioLaunch™ and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch™ platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems may include: success with proteins difficult or impossible to produce with other methods; broad applicability to biologics, including therapeutic proteins and vaccines; production time measured in weeks instead of months or more.  Additional benefits may include surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production.  The iBioModulator™ platform is complementary to the iBioLaunch™ platform and is designed to significantly improve vaccine products by increasing potency and lengthening duration of effect.  The iBioModulator™ platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com.

Forward-Looking Statements 

Various statements in this release concerning iBio's future expectations, plans and prospects, including without limitation, iBio's views with respect to the offering from time to time of its common stock and the use of the offering proceeds constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, without limitation, iBio's ability to successfully complete all or part of this offering and iBio's ability to establish and maintain strategic business alliances and new business initiatives, as well as those risks more fully discussed in the "Risk Factors" section of the prospectus supplement related to this offering, the accompanying prospectus and documents incorporated therein filed with the Securities and Exchange Commission.  In addition, any forward-looking statements represent iBio's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.  iBio does not assume any obligation to update any forward-looking statements.

Contacts

iBio, Inc.

Andrea Corcoran ,
Sr. V.P., Finance and Strategy
302-355-0624
acorcoran@ibioinc.com

Douglas Beck , CPA,
Chief Financial Officer
302-355-0923
dbeck@ibioinc.com


'/>"/>
SOURCE iBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceuticals Announces $1.5 Million Second Closing in Private Placement
2. Cardica Announces Fiscal 2013 Second Quarter Financial Results
3. Oclaro Announces Second Quarter Fiscal Year 2013 Financial Results
4. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
5. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
6. Blue Belt Technologies Announces First U.S. Sale of NavioPFS Surgical System
7. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
8. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
9. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
10. Kemwell Announces Successful Pre-NDA US FDA Inspection
11. Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Tenn. , May 26, 2016 /PRNewswire/ ... of software and analytics, network solutions and ... today announced it entered into a strategic ... provider of outpatient software solutions and revenue ... centers, specialty hospitals and rehabilitation clinics to ...
(Date:5/25/2016)... , May 25, 2016 According ... by Type (3D, 2D, 4D), by Therapeutic Area (Oncology, ... End User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast ... global Medical Animation Market for the forecast period of ... USD 301.3 Million by 2021 from USD 117.3 Million ...
(Date:5/25/2016)... 25, 2016  Zymo Research Corp. announced today ... reference materials that help researchers obtain the most ... analyses. The rapid growth of the study of ... have standard methods to improve the reproducibility and ... exist at every step of the measurement process ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 2016 , ... Beleza Medspa has initiated a new program to ... the first time that Coolsculpting is being used for for more than just cosmetic ... they meet the prescribed body-fat standard, measured by the circumference-based tape method. The ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... in intellectual property (IP) to its specialty academic programs. , Answering to the ... college’s existing certificate programs in health law, and environmental and land use law. ...
(Date:5/26/2016)... ... 2016 , ... There are nearly 14.5 million people living with and beyond ... Sunday, June 5, 2016, communities around the world will gather to recognize these cancer ... Cancer Survivors Day® is an annual worldwide Celebration of Life that is held on ...
(Date:5/26/2016)... ... ... In an effort to provide hair restoration information to the widest possible audience, Dr. Parsa ... not use the app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making ... , Dr. Mohebi says, “The positive response to the Snapchat videos we started last month ...
Breaking Medicine News(10 mins):